IMC Immuron

Immuron achieves record half yearly Travelan® sales

Immuron achieves record half yearly Travelan® sales

Highlights:

  • Record half yearly Travelan® sales of $2,334,969
  • Total sales of A$2,355,580 in H1, FY24
    • $1,771,932 increase on H1, FY23 sales
    • 51% higher than pre-pandemic period H1, FY20 sales

MELBOURNE, Australia, Jan. 16, 2024 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce record half yearly sales (unaudited net sales) of its over-the-counter gastrointestinal and digestive health immune supplement Travelan®.

Australia

Sales of Travelan® increased to AUD $1,853,048 in H1, FY24, compared to AUD $260,205 in H1, FY23. Sales increased by $1,054,164 (132%) on the pre-pandemic peak period (H1, FY20).

This increase partially reflects 3 months (May, June, July) of backorders accrued while awaiting GMP Clearance from the TGA.

Australian Bureau of Statistics: short term resident returns in October 2023 were 47% higher than October 2022 and approaching pre-pandemic levels (93% of October 2019)1.

USA

Sales of Travelan® increased to AUD $481,920 in H1, FY24, compared to AUD $295,411 in H1, FY23. Sales were lower by $31,633 (-6%) on the pre-pandemic peak period (H1, FY20).

International Trade Administration Total U.S. citizen international visitor departures from the United States in September 2023 were 17% higher than in September 2022. 2

Immuron’s target departure markets 3, July - September 2023 departures were 1% higher than the pre-pandemic period July - September 2019. 2

Immuron previously reported (July 5, 2023) that it had shipped inventory to Amazon for launch in USA. The Amazon launch continues to progress well with sales ahead of budget. We are now entering the low travel season in USA. Immuron anticipates sales to grow strongly closer to the peak spring / summer travel period.

  3. Caribbean, Asia, South America, Central America, Africa, Mexico

This release has been authorised by the directors of Immuron Limited.

COMPANY CONTACT:

Steven Lydeamore

Chief Executive Officer

Ph: +61 (0)3 9824 5254

About Immuron

Immuron Limited (ASX: IMC, NASDAQ: IMRN), is an Australian biopharmaceutical company focused on developing and commercializing orally delivered targeted polyclonal antibodies for the treatment of inflammatory mediated and infectious diseases.

For more information visit:



EN
16/01/2024

Underlying

IMCImmuron

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Immuron

 PRESS RELEASE
Free
IMC IMMURON

Immuron partners with InvestorHub

Immuron partners with InvestorHub MELBOURNE, Australia, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) advises it has entered into a partnership with InvestorHub, a direct-to-investor engagement software company that provides public companies the digital capabilities to build direct and interactive relationships with investors. In line with the Company’s commitments to better inform and engage with investors and stakeholders, we have launched our interactive investor hub - bringing content and communication into a single integrated platform. The Company will...

August 27, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron - FY25 global sales exceed projection, up 49% on prior year

Immuron - FY25 global sales exceed projection, up 49% on prior year Sales Highlights (unaudited): Global Annual sales AUD$7.3 million up 49% on prior yearJune 2025 Quarter AUD$2.0 million up 55% on prior year Australia Annual sales AUD$5.2 million up 40% on prior yearJune 2025 Quarter AUD$1.5 million up 58% on prior year North America Annual sales AUD$2.0 million up 76% on prior yearJune 2025 Quarter AUD$0.5 million up 49% on prior year MELBOURNE, Australia, July 17, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmace...

July 17, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron Letter to Shareholders: Projects Update

Immuron Letter to Shareholders: Projects Update Highlights: Immuron on track to exceed A$7 million in Sales this financial yearUniformed Services University anticipates topline results of Travelan® clinical study in October 2025Immuron anticipates IMM-529 (Clostridiodes difficile infection) IND submission to the FDA in August 2025Launch plans underway for ProIBS® in AustraliaImmuron anticipates IMM-986 (Vancomycin-resistant enterococci) pre-clinical research results in August 2025 MELBOURNE, Australia, May 30, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: I...

May 30, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron Travelan® highest sales in history

Immuron Travelan® highest sales in history Sales Highlights (unaudited): Global Immuron exceeds AUD$5 million in sales in a fiscal year - highest sales in historyMarch 2025 Quarter AUD$1.3 million up 2% on prior yearMarch 2025 Year to Date AUD$5.3 million up 46% on prior year Australia March 2025 Quarter AUD$0.8 million down 8% on prior yearMarch 2025 Year to Date AUD$3.7 million up 34% on prior year North America March 2025 Quarter AUD$0.5 million up 28% on prior yearMarch 2025 Year to Date AUD$1.6 million up 86% on prior year MELBOURNE, Australia, April 10, 2025 (GLOBE NEWSWIRE...

April 10, 2025 1 EN
 PRESS RELEASE
Free
IMC IMMURON

Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS)

Immuron and Calmino join up to treat Irritable Bowel Syndrome (IBS) MELBOURNE, Australia, March 05, 2025 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biopharmaceutical company is pleased to announce it has entered into an exclusive distribution agreement for the territories of Australia and New Zealand. Immuron will launch ProIBS® for the treatment of symptoms related to IBS in the retail pharmacy sales channel. Immuron has been a leader in digestive health in Australia for many years. ProIBS® will join Immuron’s product portfol...

March 5, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch